Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zn regulated GTPase metalloprotein activator 1E (ZNG1E) is a zinc metallochaperone that belongs to the COG0523 GTPase protein family[2]. It enables GTPase activity and transfers zinc ions to specific metalloproteins, particularly activating methionine aminopeptidase METAP1 in a zinc- and GTP hydrolysis-dependent manner[2][1][5]. This function is especially important for cellular zinc homeostasis and protein maturation, notably under zinc-starved conditions[2]. ZNG1E is predicted to reside in the nucleus and cytoplasm. Loss of ZNG1E in animal models leads to impaired cell proliferation and mitochondrial dysfunction under conditions of zinc deficiency, demonstrating its role in organismal zinc homeostasis, but it is not currently recognized as a drug target or directly associated with major human diseases[2][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zn regulated GTPase metalloprotein activator 1E (ZNG1E).